(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 October 2005 (20.10.2005)

PCT

(10) International Publication Number
WO 2005/097098 A3

(51) International Patent Classification[7]: A61K 31/192, 31/426, A61P 25/02, 25/28

(21) International Application Number:
PCT/US2005/010371

(22) International Filing Date: 29 March 2005 (29.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/558,533 1 April 2004 (01.04.2004) US

(71) Applicant *(for all designated States except US)*: **AVENTIS PHARMACEUTICALS INC.** [US/US]; 300 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807-2854 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CHANDROSS, Karen** [US/US]; 13 Staudt Court, Somerset, NJ 08873 (US). **MERRILL, Jean** [US/US]; 101 Alpine Lane, Whippany, New Jersey 07981 (US). **MINNICH, Anne** [US/US]; 2 Knoll Court, Flemington, NJ 08822 (US). **LEE, Lan** [US/US]; Box 230 Pluckemin Park, Pluckemin, NJ 07978 (US). **KHORKOVA, Olga** [US/US]; 570 Manchester Avenue, North Haledon, New Jersey 07508 (US). **LIU, Yun** [CN/US]; 42 McBride Way, Bridgewater, NJ 08807 (US).

(74) Agents: **STRUPCZEWSKI, Joseph** et al.; sanofi-aventis, Route 202-206, P. O. Box 6800, Bridgewater, NJ 08807-0800 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*
— *of inventorship (Rule 4.17(iv)) for US only*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
22 December 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF PPR DELTA AGONISTS FOR TREATING DEMYELINATING DISEASES

(57) Abstract: A method for treating demyelinating diseases in a patient in need thereof by treatment with an effective amount of a PPAR delta agonist is disclosed. Demyelinating diseases that may be effectively treated by this method include but are not limited to multiple sclerosis, Charcot-Marie-Tooth disease, Pelizaeus-Merzbacher disease, encephalomyelitis, neuromyelitis optica, adrenoleukodystrophy, Guillian-Barre syndrome and disorders in which myelin forming glial cells are damaged including spinal cord injuries, neuropathies and nerve injury.

WO 2005/097098 A3